Inflammatory bowel disease. research hub
10 indexed studies · 7 currently recruiting
- recruitingHuman Pharmacology (Phase I)- Other
A study to learn how the study medicine called [14C]PF-07054894 is processed by the body.
This study is looking at a new medicine called [14C]PF-07054894. It's for inflammatory bowel disease. We want to understand how your body handles this medicine, like how it's absorbed, changed, and leaves your system. This helps us learn more about it.
Netherlands - completed
Redesigning a faster pathway to inflammatory bowel disease (IBD) diagnosis
This study aims to find quicker ways to diagnose Inflammatory Bowel Disease (IBD). It's testing if a home stool test, sent directly to people with gut symptoms, can help identify IBD sooner, reducing the long wait many currently face before diagnosis.
United Kingdom · England - recruitingHuman Pharmacology (Phase I)- Other
A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin
This study is looking into a new medication called PF-07054894 for people with inflammatory bowel disease, specifically those of Japanese origin. It's an early-stage study to understand how the medicine works in the body.
Belgium - recruiting
Better understanding of the causes, how best to treat and how to develop new medications for Crohn’s and colitis by studying human cells and gut microbes
This study aims to better understand Crohn's and colitis by looking at cells and gut germs in people with these conditions. It hopes to discover why people's experiences differ, improve treatments, and help patients and doctors make personalized choices.
United Kingdom · England - recruitingPhase IV
Optimizing herpes zoster vaccination in immunosuppressed patients with inflammatory bowel disease
This study looks at how to make the shingles vaccine work best for people with Inflammatory Bowel Disease (IBD) who take certain medications. It explores if briefly pausing their medication helps the vaccine be more effective.
United Kingdom · England · Scotland - active not recruiting
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
This study looks at how well people with Inflammatory Bowel Disease (IBD) stay on a medicine called Hyrimoz® for up to six months. It helps us understand how the medicine works in real life.
Belgium · France - recruiting
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
This study looks at how a medicine called guselkumab works for people in Germany with Crohn's disease or ulcerative colitis in real life. It also checks how this medicine affects their quality of life, tiredness, and daily activities.
Germany - recruiting
Characterization of Phenotype and Genotype of Early Onset Enteropathies
This study looks at children and their families who have a serious gut condition that starts early in life, sometimes called inflammatory bowel disease. Researchers want to understand why these conditions happen by studying genes and other factors. They hope to find new ways to help people keep their guts healthy.
France - recruiting
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
This study looks at how well a medicine called guselkumab works for adults with moderate to severe Ulcerative Colitis or Crohn's Disease in the UK. Researchers want to see its real-world benefits and how different groups of patients respond.
United Kingdom - authorisedTherapeutic use (Phase IV)
Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial
This study looks at children and teenagers with Inflammatory Bowel Disease who are starting treatment with a medicine called infliximab. Researchers want to see if checking medicine levels early helps the treatment work better and for longer, compared to usual care.
Italy